Triethylenetetramine
- Generic Name
- Triethylenetetramine
- Brand Names
- Cuvrior, Syprine, Cuprior, Cufence
- Drug Type
- Small Molecule
- Chemical Formula
- C6H18N4
- CAS Number
- 112-24-3
- Unique Ingredient Identifier
- SJ76Y07H5F
- Background
Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, spermidine and spermine. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease, TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.
TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.
- Indication
Triethylenetetramine is a copper chelator indicated for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.
- Associated Conditions
- Wilson's Disease
- Associated Therapies
- -
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Manchester University NHS Foundation Trust
- Target Recruit Count
- 154
- Registration Number
- NCT04706429
- Locations
- 🇬🇧
University Hospitals of Leicester NHS Foundation Trust, Leicester, United Kingdom
🇬🇧Liverpool Heart and Chester Hospital NHS Foundation Trust, Liverpool, United Kingdom
🇬🇧Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients
- Conditions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Excelsior
- Target Recruit Count
- 48
- Registration Number
- NCT03299829
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan
Trientine and Carboplatin in Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT01178112
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Tetrathiomolybdate in Patients With Wilson Disease
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2006-05-09
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 90
- Registration Number
- NCT00004339
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.